Sientra Inc (SIEN) Given Consensus Rating of “Buy” by Brokerages

Shares of Sientra Inc (NASDAQ:SIEN) have been assigned a consensus rating of “Buy” from the thirteen analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation and seven have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $20.44.

A number of brokerages have recently commented on SIEN. Wells Fargo & Co began coverage on Sientra in a research report on Thursday. They set a “market perform” rating and a $9.00 price objective for the company. ValuEngine downgraded Sientra from a “buy” rating to a “hold” rating in a research report on Thursday. Stifel Nicolaus lowered their price objective on Sientra from $19.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday. Dougherty & Co lowered their price objective on Sientra from $29.00 to $27.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Leerink Swann lowered their price objective on Sientra from $22.00 to $18.00 in a research report on Wednesday.

Shares of Sientra stock opened at $8.84 on Friday. Sientra has a one year low of $7.74 and a one year high of $26.79. The stock has a market cap of $252.82 million, a PE ratio of -2.72 and a beta of -0.04. The company has a debt-to-equity ratio of 0.36, a current ratio of 2.77 and a quick ratio of 2.34.

Sientra (NASDAQ:SIEN) last announced its quarterly earnings data on Tuesday, March 12th. The medical instruments supplier reported ($0.86) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.19). Sientra had a negative return on equity of 123.50% and a negative net margin of 121.28%. The company had revenue of $19.02 million for the quarter, compared to analyst estimates of $18.87 million. On average, sell-side analysts predict that Sientra will post -2.52 earnings per share for the current year.

A number of hedge funds have recently bought and sold shares of SIEN. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Sientra during the fourth quarter worth approximately $29,000. Great West Life Assurance Co. Can purchased a new stake in Sientra during the fourth quarter worth approximately $64,000. Metropolitan Life Insurance Co. NY lifted its stake in Sientra by 356.6% during the fourth quarter. Metropolitan Life Insurance Co. NY now owns 8,191 shares of the medical instruments supplier’s stock worth $104,000 after purchasing an additional 6,397 shares during the last quarter. Dimensional Fund Advisors LP purchased a new stake in Sientra during the fourth quarter worth approximately $135,000. Finally, HRT Financial LLC purchased a new stake in Sientra during the fourth quarter worth approximately $157,000. Hedge funds and other institutional investors own 92.79% of the company’s stock.

Sientra Company Profile

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Recommended Story: Return On Assets

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.